Navigation Links
Patient's own infection-fighting T cells put late-stage melanoma into long-term remission
Date:6/18/2008

SEATTLE Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.

Yee and colleagues removed CD4+ T cells, a type of white blood cell, from a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung. T cells specific to targeting the melanoma were then expanded vastly in the laboratory using modifications to existing methods. The lab-grown cells were then infused into the patient with no additional pre- or post-conditioning therapies, such as growth-factor or cytokine treatment. Two months later, PET and CT scans revealed no tumors. The patient remained disease free two years later, when he was last checked.

"We were surprised by the anti-tumor effect of these CD4 T cells and its duration of response," Yee said. "For this patient we were successful, but we would need to confirm the effectiveness of therapy in a larger study."

Yee cautioned that these results, presented in the journal's "Brief Report" section, represent only one patient with a specific type of immune system whose tumor cells expressed a specific antigen. More studies are needed to confirm the effectiveness of the experimental T-cell therapy. If proven successful in more patients, Yee predicted this therapy could be used for the 25 percent of all late-stage melanoma patients who have the same immune-system type and tumor antigen.

Using a patient's own immune system to combat cancer, called immunotherapy, is a growing area of research that aims to develop less-toxic cancer treatments than standard chemotherapy and radiation.

The patient in the journal report was one of nine patients
'/>"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. World Renowned Hand Surgeon Helps Patients Conquer Joint Discomfort Naturally
2. FDA Panel Recommends Enbrel for Pediatric Patients
3. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
4. Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ESGAR 2008
5. Patient Data Analysis Report Finds More Than 75 Percent of Chronically Ill Patients Unable to Obtain Needed Healthcare Have Some Form of Insurance
6. Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
7. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
8. Same-day pregnancy test provides valuable guidance to pre-surgery patients
9. Future hope for patients with breast cancers resistant to tamoxifen
10. Some patients may not need insulin for long-term control of type 2 diabetes
11. Nurses, Doctors, Patients to Protest Health Insurers at National Day of Action - June 19th
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 1The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 2The People 26apos 3Bs Medicine Community Certified to Display TRUSTe Privacy Seal of Approval 55795 3Two Powerful Companies One Powerhouse in Protection 55790 1Two Powerful Companies One Powerhouse in Protection 55790 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 1Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 2Chemotherapy for breast cancer is associated with disruption of sleep wake rhythm in women 55788 3